WO2008008057A1 - Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci - Google Patents

Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci Download PDF

Info

Publication number
WO2008008057A1
WO2008008057A1 PCT/US2006/026899 US2006026899W WO2008008057A1 WO 2008008057 A1 WO2008008057 A1 WO 2008008057A1 US 2006026899 W US2006026899 W US 2006026899W WO 2008008057 A1 WO2008008057 A1 WO 2008008057A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical ingredient
active pharmaceutical
pharmaceutical composition
moisture sensitive
binder
Prior art date
Application number
PCT/US2006/026899
Other languages
English (en)
Inventor
Michael Fox
Original Assignee
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Usa, Inc. filed Critical Teva Pharmaceutical Industries Ltd.
Priority to JP2009519417A priority Critical patent/JP2009542806A/ja
Priority to CNA2006800552443A priority patent/CN101478983A/zh
Priority to CA002659814A priority patent/CA2659814A1/fr
Priority to MX2009000358A priority patent/MX2009000358A/es
Priority to BRPI0621867-9A priority patent/BRPI0621867A2/pt
Priority to PCT/US2006/026899 priority patent/WO2008008057A1/fr
Publication of WO2008008057A1 publication Critical patent/WO2008008057A1/fr
Priority to IL196273A priority patent/IL196273A0/en
Priority to NO20090609A priority patent/NO20090609L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Definitions

  • the present invention relates to stable pharmaceutical compositions comprising a combination of a moisture sensitive active pharmaceutical ingredient (drug), in particular an angiotensin converting enzyme (ACE) inhibitor such as Cilazapril, and a second drug, such as Hydrochlorothiazide, as the active ingredients and methods for preparing such stable pharmaceutical compositions.
  • a moisture sensitive active pharmaceutical ingredient drug
  • an angiotensin converting enzyme (ACE) inhibitor such as Cilazapril
  • ACE angiotensin converting enzyme
  • Hydrochlorothiazide a second drug, such as Hydrochlorothiazide
  • Cilazapril is apparently an angiotensin converting enzyme ("ACE") inhibitor, which enzyme inhibits the formation of angiotensin II from angiotensin I by inhibiting the angiotensin converting enzyme.
  • ACE angiotensin converting enzyme
  • Cilazapril is reported to be (1S,9S)- 9-[(S)- 1 -Ethoxycarbonyl-3 -phenylpropylamino]- 10-oxoperhydropyridazino[ 1 ,2- a][l,2]diazepine-l- carboxylic acid and is understood to be disclosed in U.S. Patent No. 4,512,924.
  • Cilazapril has been prescribed in treating patients suffering from hypertension.
  • Cilazapril has the following general formula:
  • Hydrochlorothiazide is apparently a diuretic and an antihypertensive. Chemically, Hydrochlorothiazide, a 3,4-dihydro derivative of chlorothiazide, is reported to be 6-chloro-3,4-dihydro-2H-l,2,4-benzothiazidine-7-sulfonamide 1,1- dioxide and has the following general formula.
  • Hydrochlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Further, Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
  • a stable pharmaceutical composition does not exhibit substantial decomposition of the active pharmaceutical ingredient during the time between the manufacture of the composition and its use by a patient.
  • Cilazapril and a number of other drugs suffer from instability problems because the active pharmaceutical ingredient rapidly degrades in the presence of water/moisture.
  • Such active pharmaceutical ingredients can therefore be characterized as moisture- sensitive drugs.
  • tablet blends may be dry mixed, dry-granulated or wet- granulated before tableting.
  • the choice of the processing procedure, dry mixing, dry granulation, wet granulation, or some other granulation process, depends on the properties of the drug and the chosen excipients. Generally, a dry manufacturing process is thought to be preferable for moisture-sensitive drugs.
  • water scavenger compounds may be incorporated into a tablet matrix.
  • a water scavenger compound is the binder Copovidone (Plasdone S-630 ® ), which binder is specifically recommended for moisture sensitive drugs.
  • Plasdone S-630 ® binder Copovidone
  • Cilazapril tablets using this material in a dry granulation process.
  • degradation of the active pharmaceutical ingredient was apparent.
  • Wet-granulation processes have not been considered appropriate for moisture sensitive drugs since the very nature of these processes can include the presence of water/moisture.
  • compositions of such moisture sensitive active pharmaceutical ingredients may contain one or more additional drug substances in a combination pharmaceutical composition.
  • Such combination pharmaceutical compositions could provide enhanced treatment effectiveness or provide treatment while ameliorating undesired side effects of one such moisture sensitive active pharmaceutical ingredient.
  • the combination of active pharmaceutical ingredients in one composition requires that the active pharmaceutical ingredients are compatible in terms of activity, side effects, and effectiveness for example.
  • Hydrochlorothiazide can be used in combination with other antihypertensives.
  • pharmaceutical compositions for use in the treatment of hypertension may comprise a combination of Hydrochlorothiazide and an antihypertensive agent.
  • HCTZ is compatible with the moisture sensitive active pharmaceutical ingredient Cilazapril for inclusion in a combination pharmaceutical composition.
  • a pharmaceutical composition comprising a moisture sensitive drug substance and a second drug substance prepared using a single wet granulation process of the combined active ingredients appeared not to be a stable pharmaceutical composition but showed degradation of Cilazapril.
  • a wet granulation process for preparing the combination pharmaceutical composition will be divided in at least two steps, wherein the second drag substance, preferably Hydrochlorothiazide (HCTZ), is added to the wet granulate after the wet granulation of the moisture sensitive drag substance, preferably Cilazapril, is completed.
  • the second drag substance preferably Hydrochlorothiazide (HCTZ)
  • HCTZ Hydrochlorothiazide
  • the present invention provides stable pharmaceutical compositions of a combination of Cilazapril and Hydrochlorothiazide (HCTZ), and methods of their preparation.
  • HCTZ Hydrochlorothiazide
  • the present invention provides a stable pharmaceutical composition
  • a stable pharmaceutical composition comprising; a) a moisture sensitive active pharmaceutical ingredient; and b) a second active pharmaceutical ingredient; wherein the moisture sensitive active pharmaceutical ingredient is first wet granulated with a solution of at least one pharmaceutical excipient in at least one processing solvent before granulation with the second active pharmaceutical ingredient.
  • at least one excipient is a binder.
  • the present invention provides a method of preparing a combined granular composition comprising a wet granulated moisture sensitive active pharmaceutical ingredient and a second active pharmaceutical ingredient comprising the following steps of a) providing a moisture sensitive active pharmaceutical ingredient; b) mixing the moisture sensitive active pharmaceutical ingredient with at least one pharmaceutically acceptable excipient other than a binder, forming a mixture; and c) wet granulating the mixture with a solution of a binder excipient dissolved in one or more processing solvents forming a wet granulate; d) providing a material comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutical excipients; and e) adding the material from step d) to the wet granulate from step c) forming a combined granulate, wherein when the material of step d) comprises a second pharmaceutical ingredient and one or more pharmaceutical excipients the material is optionally a mixture obtained by mixing the second pharmaceutical ingredient with the one or more pharmaceutical excipient.
  • the method further comprises steps of preparing a tablet pharmaceutical composition of the present invention wherein the method further comprises the steps of f) mixing the combined granulate with one or more excipients forming a final blend; g) pressing the final blend into a tablet; and h) optionally coating the tablet with a cosmetic coat.
  • the present invention also provides a method of treating a patient suffering from a disease, preferably hypertension, comprising administering to a patient in need thereof a therapeutically effective amount of a stable pharmaceutical composition comprising a moisture sensitive active pharmaceutical ingredient, preferably Cilazapril, a second active pharmaceutical ingredient, preferably Hydrochlorothiazide, and at least one pharmaceutical excipient, wherein the active pharmaceutical ingredients are wet granulated with a solution of the at least one pharmaceutical excipient.
  • a moisture sensitive active pharmaceutical ingredient preferably Cilazapril
  • a second active pharmaceutical ingredient preferably Hydrochlorothiazide
  • moisture sensitive active pharmaceutical ingredient refers to an active pharmaceutical ingredient which rapidly degrades in the presence of water/ moisture.
  • moisture sensitive active pharmaceutical ingredient it is helpful to consider how the exemplified Cilazapril behaves on storage.
  • compositions of such moisture sensitive active pharmaceutical ingredients may contain one or more additional drug substances in a combination pharmaceutical composition.
  • Such combination pharmaceutical compositions could provide enhanced treatment effectiveness or provide treatment while ameliorating undesired side effects of one such moisture sensitive active pharmaceutical ingredient.
  • the combination of active pharmaceutical ingredients in one composition requires that the drug substances are compatible in terms of activity, side effects, and effectiveness for example.
  • a compatible second drug substance for inclusion in a combination pharmaceutical composition comprising the moisture sensitive drug substance Cilazapril, is for example Hydrochlorothiazide (HCTZ).
  • a pharmaceutical composition comprising a moisture sensitive drug substance and a second drug substance using wet granulation of the combined drug substances appeared not to be a stable pharmaceutical composition, hi particular, such pharmaceutical composition containing only Cilazapril as its active pharmaceutical ingredrient was shown to be stable but showed unacceptable degradation to Cilazaprilat, when Cilazapril was combined with a second drug substance such as HCTZ in a composition where a combined mixture of the drug substances was wet granulated.
  • a wet granulation process for preparing the combination pharmaceutical composition will be divided in at least two steps, wherein the second drag substance, preferably Hydrochlorothiazide (HCTZ), is added to the wet granulate after first the granulation of the moisture sensitive drag substance, preferably Cilazapril, is completed.
  • HCTZ can be added to the wet granulate alone or together with other ingredients and/or in a granulation solution.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising; a) a moisture sensitive active pharmaceutical ingredient, preferably Cilazapril; and b) a second active pharmaceutical ingredient, preferably Hydrochlorothiazide;
  • compositions of this aspect of the invention are stable.
  • the first wet granulation step should preferably not involve a significant proportion of the second active pharmaceutical ingredient, and most preferably does not contain any of the second active pharmaceutical ingredient.
  • at least one excipient is a binder and the pharmaceutical composition comprises at least two pharmaceutical excipients.
  • the amount of the moisture sensitive active pharmaceutical ingredient in the composition is about 0.1% to about 25%, more preferably about 0.5% to about 15%, of the total weight of the composition.
  • a most preferred amount of the moisture sensitive active pharmaceutical ingredient in the composition is about 0.6% to about 2.7% of the total weight of the composition.
  • the moisture sensitive active pharmaceutical ingredient is Cilazapril.
  • the amount of the second active pharmaceutical ingredient in the composition is about 1% to about 25%, more preferably of about 3% to about 15%, of the total weight of the composition.
  • a most preferred amount of the second active pharmaceutical ingredient in the composition is about 5% to about 10% of the total weight of the composition.
  • the second active pharmaceutical ingredient is preferably a diuretic drug. More preferably a thiazide derivative. Most preferably Hydrochlorothiazide (HCTZ).
  • the present invention further provides a stable pharmaceutical composition
  • a stable pharmaceutical composition comprising a moisture sensitive active pharmaceutical ingredient, a second active pharmaceutical ingredient and at least one pharmaceutically acceptable excipient, wherein the composition contains not more than 3% (w/w of the initial amount of the moisture sensitive active pharmaceutical ingredient) of a major degradation product after storage in a package with moisture barrier properties which properties are at least as efficient as aluminum-aluminum cold form blisters.
  • the concentration of the major degradation product in the stable pharmaceutical composition of the present invention after storage as described above is not more than 2%. More preferably, the concentration of the major degradation product in the stable pharmaceutical composition of the present invention after storage as described above is not more than 1%.
  • Storage may comprise storage at a temperature of 55 0 C for 14 days and storage at a temperature of 40°C and 75% relative humidity for three months.
  • the degradation product may be detected by HPLC analysis.
  • the moisture sensitive active pharmaceutical ingredient is Cilazapril and the degradation product is its major degradation product Cilazaprilat.
  • the second pharmaceutical ingredient is HCTZ.
  • a stable pharmaceutical composition of the present invention therefore provides a pharmaceutical composition of a moisture sensitive active pharmaceutical ingredient and a second pharmaceutical ingredient, preferably Cilazapril and HCTZ respectively, characterized by comprising not more than 3%, preferably not more than 2%, most preferably not more than 1%, by weight per weight of the total amount of moisture sensitive pharmaceutical ingredient, Cilazapril, of its major degradation Cilazaprilat product upon storage.
  • Cilazaprilat has the following structure:
  • the stable pharmaceutical composition of the present invention comprises at least about 4% of a binder by total weight of the composition.
  • the pharmaceutical composition comprises from about 4% to about 20%, more preferably from about 5% to about 10% of a binder by total weight of the composition.
  • the binder comprises for example, one or more of, a cellulose derivative, a polyvinyl pyrrolidone (PVP) and its derivatives, a polyvinylacetate (PVA) or a polyvinyl alcohol.
  • suitable cellulose derivatives as a binder in the present invention are Hydroxypropyhnethyl cellulose (HPMC) or Hydroxypropyl cellulose (HPC).
  • the binder is the Copovidone, exemplified by Plasdone ® S-630 (Copovidone), which is a synthetic, 60:40, linear, random copolymer of N-vinyl-2-pyrrolidone and vinyl acetate, and which has a reduced hydrophilicity and a reduced polymer glass transition temperature (Tg) in comparison to a polyvinyl pyrrolidone (PVP) homopolymer.
  • this binder is wet granulated with the moisture sensitive active pharmaceutical ingredient and one or more pharmaceutical excipients in a processing solvent to form a wet granulate before granulating the wet granulate with a second drug substance.
  • the stable pharmaceutical compositions comprising a moisture sensitive active pharmaceutical ingredient and a second drug substance of the present invention may further contain excipients such as tablet and capsule fillers and diluents (such as microcrystallme cellulose, lactose, starch and tri-basic calcium phosphate), disintegrants (such as starch, croscarmellose sodium, crospovidone and sodium starch glycolate), and glidants (such as colloidal silicon dioxide and talc), lubricants (such as magnesium stearate, sodium lauryl sulfate, stearic acid and sodium stearyl fumarate). More particularly, suitable diluents and fillers for use in the pharmaceutical composition of the present invention include microcrystalline cellulose (e.g.
  • Avicel ® lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, powdered cellulose, sodium chloride, sorbitol and talc.
  • the pharmaceutical composition of the present invention includes lactose monohydrate, more preferably in an amount of about 50% to about 65%, most preferably of about 55% to about 60% by total weight of the composition.
  • the pharmaceutical composition of the present invention includes talc, more preferably in an amount of about 1% to about 2% by total weight of the composition.
  • the pharmaceutical composition may also include both lactose monohydrate and talc in the amounts specified above.
  • Solid pharmaceutical compositions of the present invention that are compacted into a dosage form, such as a tablet, may include the addition of a disintegrant to the composition.
  • Disintegrants include croscarmellose sodium (e.g. Ac Di Sol ® , Primellose ® ), crospovidone (e.g. Kollidon ® , Polyplasdone ® ), microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium starch glycolate (e.g. Explotab , Primoljel ® ) and starch.
  • the pharmaceutical composition of the present invention includes starch, more preferably in an amount of about 20% to about 30%, most preferably about 25% by total weight of the composition.
  • Glidants can be added to improve the flowability of a solid composition before compaction and to improve the accuracy of dosing especially during compaction and capsule filling.
  • Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, and talc.
  • a lubricant can be added to the composition to reduce adhesion and/or ease the release of the product from e.g. the dye.
  • Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
  • the pharmaceutical composition of the present invention includes sodium stearyl fumarate, more preferably in an amount of about 0.5% to about 1.5%, most preferably about 1% by total weight of the composition.
  • excipients that may be incorporated into the formulation include preservatives, surfactants, antioxidants, or any other excipient commonly used in the pharmaceutical industry.
  • the stable formulation comprises Cilazapril, HCTZ, copovidone, lactose monohydrate, sodium starch glycolate, talc extra fine and sodium stearyl fumarate.
  • the pharmaceutical composition comprises (by total weight of the composition), Cilazapril in an amount of about 0.5% to about 15%, more preferably of about 0.6% to about 2.7%, HCTZ in an amount of about 3% to about 15%, more preferably of about 5% to about 10%, lactose monohydrate in an amount of about 50% to about 65%, more preferably of about 55% to about 60%, talc in an amount of about 1% to about 2%, starch in an amount of about 20% to about 30%, more preferably about 25%, a binder, preferably copovidone, in an amount of about 4% to about 20%, more preferably 5% to 10%, and sodium stearyl fumarate in an amount of about 0.5% to about 1.5%, more preferably about 1%.
  • the solid compositions of the present invention include powders, granulates, aggregates and compacted compositions.
  • the dosages include dosages suitable for oral, buccal, and rectal administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral.
  • the dosages may be conveniently presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical arts.
  • the pharmaceutical composition of the present invention may be prepared in any dosage form such as a compressed granulate in the form of a tablet for example. Also, uncompressed granulates and powder mixes that are obtained by the method of the present invention in the pre-compression steps can be simply provided in a dosage form of a capsule or sachet.
  • dosage forms of the pharmaceutical composition of the present invention include solid dosage forms like tablets, powders, capsules, sachets, etc.
  • the dosage form of the present invention may also be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell.
  • the shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
  • a solid composition comprising a moisture sensitive active pharmaceutical ingredient, preferably Cilazapril, and a second drug substance, preferably HCTZ, is prepared in accordance with the present invention, it is preferably formulated into pharmaceutical formulations such as conventional dosage forms, including tablets and capsules. Tablets are a preferred dosage form.
  • the tablets may be coated with an optional cosmetic tablet coating. More preferably this cosmetic coat has "moisture barrier" properties. This moisture barrier property provides protection against environmental moisture for sensitive cores, enhances product stability, and improves shelf life.
  • the cosmetic coating is a tablet coating based on polyvinyl alcohol. More preferably, the cosmetic coating comprises polyvinyl alcohol, talc and polyethylene glycol (PEG). Most preferably, the cosmetic coating further comprises an opacifier and/or a colorant, e.g. titanium dioxide and/or iron oxide.
  • the tablets of the present invention comprises a cosmetic coat of about 2% to about 6% of the tablet weight, more preferably of about 2.5% to about 4.5% of the tablet weight, most preferably of about 3% to about 3.5% of the tablet weight.
  • the present invention provides a method of preparing a pharmaceutical composition comprising a moisture sensitive active pharmaceutical ingredient and a second active pharmaceutical ingredient comprising the following steps of a) providing a moisture sensitive active pharmaceutical ingredient; b) mixing the moisture sensitive active pharmaceutical ingredient with at least one pharmaceutically acceptable excipient, forming a mixture; and c) wet granulating the mixture with a solution of a binder excipient dissolved in one or more processing solvents forming a wet granulate; d) providing a material comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutical excipients; and e) adding the material from step d) to the wet granulate from step c) forming a combined granulate, wherein when the material of step d) comprises a second pharmaceutical ingredient and one or more pharmaceutical excipients the material is optionally a mixture obtained by mixing the second pharmaceutical ingredient with the one or more pharmaceutical excipients.
  • the moisture sensitive active pharmaceutical ingredient is Cilazapril and the second active pharmaceutical ingredient is Hydrochlorothiazide (HCTZ).
  • the pharmaceutical excipient(s) employed in step b) do not include a binder.
  • the amount of the moisture sensitive active pharmaceutical ingredient in the composition is about 0.1% to about 25%, more preferably of about 0.5% to about 15%, of the total weight of the composition.
  • a most preferred amount of the moisture sensitive active pharmaceutical ingredient in the composition is about 0.6% to about 2.7% of the total weight of the composition.
  • the moisture sensitive active pharmaceutical ingredient is Cilazapril.
  • the amount of the second active pharmaceutical ingredient in the composition is about 1% to about 25%, more preferably of about 3% to about 15%, of the total weight of the composition.
  • a most preferred amount of the second active pharmaceutical ingredient in the composition is about 5% to about 10% of the total weight of the composition.
  • the second active pharmaceutical ingredient is Hydrochlorothiazide (HCTZ).
  • a typical granulation process involves mixing the moisture sensitive active ingredient and possibly excipients in a mixer.
  • the binder is dissolved in the processing solvent used for granulating although a further portion of binder or another binder may be one of the excipients added in the initial dry mix state with the moisture sensitive drug substance.
  • the granulating/ processing solvent, solution or suspension is added to the dry powders in the mixer and mixed to form a wet granulate.
  • the second drug substance is added to the wet granulate either alone or with one or more excipients, optionally in a processing solvent, and mixed until the desired characteristics are achieved.
  • the product is most often dried and then milled after drying, to obtain a major percentage of the product within a desired size range.
  • the product after wet granulation is dried until the loss on drying (LOD) is not more than about 2.5%, more preferably not more than about 1.5%.
  • the product is milled or sized through a lmm aperture screen, more preferably through a 0.8mm aperture screen.
  • the stable pharmaceutical composition of the present invention is prepared by wet granulation with a suitable solvent/processing solvent.
  • a suitable solvent/processing solvent is able to dissolve the selected binder.
  • the solvent/processing solvent is capable of dissolving the binder to reach a concentration of at least about 10% W/W. More preferably, the solvent/processing solvent is selected from the group consisting of ethanol, isopropyl alcohol, water, and combinations thereof.
  • the stable formulation prepared by wet granulation comprises at least 4%, preferably about 4% to about 20%, more preferably about 5% to about 10%, of a binder by weight of the formulation.
  • Suitable binders for use in the method of the present invention include cellulose derivatives, polyvinyl pyrrolidones (PCP) and its derivatives, polyvinylacetates (PVA), or polyvinylalcohols.
  • the binder comprises at least Copovidone and more preferably, the binder is applied as a solution in ethanol or water.
  • a preferred solution of the binder in ethanol or water comprises about 25% to about 55% (w/w) binder, preferably Copovidone, more preferably about 30% to about 50% (w/w) binder, preferably Copovidone.
  • the method of the present invention may further comprise steps in preparing a tablet or capsule of the pharmaceutical composition of the present invention.
  • the method further comprises the steps of f) mixing the combined granulate from step e) with one or more excipients forming a final blend; g) pressing the final blend into a tablet; and h) optionally coating the tablet with a cosmetic coat.
  • the cosmetic ' coat has moisture barrier properties. Examples of such cosmetic coatings are tablet coatings based on polyvinyl alcohol.
  • the optional cosmetic coating of the tablet preferably comprises preparing a suspension comprising about 10% to about 25%, preferably about 12% to about 15%, more preferably about 12% to about 13%, of a powder mixture for cosmetic coating, and applying the suspension on the tablet.
  • the cosmetic coating suspension is preferably prepared such that the tablet comprises about 2% to about 6%, preferably about 2.5% to about 4.5%, of a tablet cosmetic coat.
  • the tablet cosmetic coat in the present invention preferably has "moisture barrier" properties.
  • the commercially available series of powder mixes for coating suspension sold as the Opadry ® II 85F series, available from Colorcon, which are based on Polyvinyl alcohol, are examples of such cosmetic coat with moisture barrier properties.
  • Capsules comprising either a hard or soft shell and containing the composition of the present invention may be prepared.
  • the shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
  • a capsule filling of the present invention may comprise the granulates that were described with reference to tableting, a final blend of a granulate composition of the present invention mixed with one or more excipients, however they are not subjected to a final tableting step. Further, such capsules may be prepared by any of the methods well known in the pharmaceutical arts.
  • the present invention provides a method for preparing a stable pharmaceutical composition
  • a method for preparing a stable pharmaceutical composition comprising: a) mixing cilazapril, lactose, talc and starch; b) adding a solution of a binder, preferably copovidone, to the mixture obtained in step a) to form a wet granulate; c) optionally combining the wet granulate with further starch and mixing; d) adding HCTZ to the wet granulate and mixing; e) drying and then milling the granulate; and f) adding sodium stearyl fumarate to the granulate obtained in step e) and mixing to obtain a final blend.
  • a binder preferably copovidone
  • compositions of the present invention are useful in therapy.
  • compositions of the invention are useful in treating hypertension.
  • the present invention also provides a method of treating a patient suffering from a disease, preferably hypertension, comprising administering to a patient in need thereof a therapeutically effective amount of a stable pharmaceutical composition comprising a moisture sensitive active pharmaceutical ingredient, preferably Cilazapril, a second active pharmaceutical ingredient, preferably Hydrochlorothiazide, and at least one pharmaceutical excipient, wherein the active pharmaceutical ingredients are wet granulated with a solution of at least one pharmaceutical excipient.
  • a moisture sensitive active pharmaceutical ingredient preferably Cilazapril
  • a second active pharmaceutical ingredient preferably Hydrochlorothiazide
  • Example 1 Wet granulation, Hypromellose (HPMC) as a binder, one step granulation
  • Tablets were pressed from the final blend in a rotary tablet press. The tablets were packed in cold formed aluminium blister covered with aluminium foil. Packed tablets were stored at 55 0 C. The main degradation product, Cilazaprilat, was tested using HPLC method.
  • Example 2 Wet granulation, Copovidone as a binder, one step granulation hi a high shear mixer were mixed for 1 minute: 5.2 g of Cilazapril Monohydrate, 115.3 g of Lactose Monohydrate, 3.0 g of Talc Extra Fine, 12.5 g of Hydrochlorothiazide and 50.0 g of Starch. 33 g of a 36.4% (w/w) aqueous solution of Copovidone was added and the mass was mixed in the high shear mixer for 3 minutes. The obtained granulate was dried using a fluid bed dryer and the dry granulate was milled in an oscillating granulator through 0.8 mm screen. The milled granulate was combined with 1.6 g of screened Sodium Stearyl Fumarate and mixed in a Y-cone blender for 5 minutes.
  • Tablets were pressed from the final blend in a rotary tablet press. The tablets were packed in cold formed aluminium blister covered with aluminium foil. Packed tablets were stored at 55 0 C. The main degradation product, Cilazaprilat, was tested using HPLC method.
  • Example 3 Wet granulation, Hvpromellose (HPMC) as a binder, two steps granulation
  • the obtained granulate was dried using a fluid bed dryer and the dry granulate was milled in an oscillating granulator through 0.8 mm screen.
  • the milled granulate was combined with 3.8 g of screened Sodium Stearyl Fumarate and mixed in a Y-cone blender for 5 minutes.
  • Tablets were pressed from the final blend in a rotary tablet press. The tablets were packed in cold formed aluminium blister covered with aluminium foil. Packed tablets were stored at 55 0 C. The main degradation product, Cilazaprilat, was tested using HPLC method.
  • Example 4 Wet granulation, Copovidone as a binder, two steps granulation
  • Tablets were pressed from the final blend in a rotary tablet press. The tablets were packed in cold formed aluminium blister covered with aluminium foil.
  • Tablets were pressed from the final blend in a rotary tablet press. The tablets were packed in cold formed aluminium blister covered with aluminium foil. Packed tablets were stored at 55 0 C. The main degradation product, Cilazaprilat, was tested using HPLC method.
  • Example 6 Stability testing of pharmaceutical compositions of Cilazapril and HCTZ.
  • Comparative stability tests were performed comparing the stability of pharmaceutical compositions of Cilazapril and HCTZ prepared either in a process wet granulating a mixture of Cilazapril and HCTZ (a "single step wet granulation process") with such pharmaceutical compositions prepared in a process wet granulating first Cilazapril forming a wet granulate to which the HCTZ is added (a "two step wet granulation process").
  • Table 3 shows the results of storage of such compositions (Examples 1-5) under stress conditions of 55°C for 4 weeks. The results in the table shows that the two step wet granulation process of pharmaceutical compositions of Cilazapril and HCTZ of the present invention provides a stable pharmaceutical composition compared to the one step wet granulating process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques stables comprenant une combinaison d'ingrédients pharmaceutiques actifs. La composition pharmaceutique de la présente invention comprend un médicament sensible à l'humidité, en particulier un inhibiteur de l'enzyme de conversion de l'angiotensine (ACE) tel que le Cilazapril, en tant qu'ingrédient actif, un second ingrédient pharmaceutiquement actif tel que, par exemple, l'hydrochlorothiazide, et au moins un excipient pharmaceutique, l'ingrédient pharmaceutique actif sensible à l'humidité étant granulé par voie humide avec une solution d'au moins un excipient pharmaceutique. L'invention concerne également des procédés de préparation de ces compositions pharmaceutiques stables.
PCT/US2006/026899 2006-07-10 2006-07-10 Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci WO2008008057A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2009519417A JP2009542806A (ja) 2006-07-10 2006-07-10 感湿性薬物及び第2薬物の組合せを含んで成る安定製剤及びその製造方法
CNA2006800552443A CN101478983A (zh) 2006-07-10 2006-07-10 含有对水分敏感的药物和第二药物的组合的稳定制剂及其制造方法
CA002659814A CA2659814A1 (fr) 2006-07-10 2006-07-10 Formulation stable comprenant une combinaison d'un medicament sensible a l'humidite et d'un second medicament et procedure de fabrication de celle-ci
MX2009000358A MX2009000358A (es) 2006-07-10 2006-07-10 Formulacion estable que comprende una combinacion de un farmaco sensible a la humedad y un segundo farmaco y procedimiento de fabricacion de ella.
BRPI0621867-9A BRPI0621867A2 (pt) 2006-07-10 2006-07-10 formulação estável que consiste na combinação de uma droga sensìvel à umidade e uma segunda droga, e processo para a sua fabricação
PCT/US2006/026899 WO2008008057A1 (fr) 2006-07-10 2006-07-10 Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci
IL196273A IL196273A0 (en) 2006-07-10 2008-12-30 Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
NO20090609A NO20090609L (no) 2006-07-10 2009-02-09 Stabilt preparat omfattende en kombinasjon av et fuktighetsfolsomt legemiddel og et andre legemiddel, samt fremgangsmate for dets fremstilling

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/026899 WO2008008057A1 (fr) 2006-07-10 2006-07-10 Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci

Publications (1)

Publication Number Publication Date
WO2008008057A1 true WO2008008057A1 (fr) 2008-01-17

Family

ID=37907393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/026899 WO2008008057A1 (fr) 2006-07-10 2006-07-10 Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci

Country Status (8)

Country Link
JP (1) JP2009542806A (fr)
CN (1) CN101478983A (fr)
BR (1) BRPI0621867A2 (fr)
CA (1) CA2659814A1 (fr)
IL (1) IL196273A0 (fr)
MX (1) MX2009000358A (fr)
NO (1) NO20090609L (fr)
WO (1) WO2008008057A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
WO1993017685A1 (fr) * 1992-03-11 1993-09-16 Merck & Co., Inc. Combinaisons d'inhibiteurs de l'enzyme de conversion de l'angiotensine et de diuretiques
WO2003075842A2 (fr) * 2002-03-08 2003-09-18 Teva Pharmeceuticals Usa, Inc. Formulations stables d'inhibiteurs de l'enzyme de conversion de l'angiotensine (ace)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
WO1993017685A1 (fr) * 1992-03-11 1993-09-16 Merck & Co., Inc. Combinaisons d'inhibiteurs de l'enzyme de conversion de l'angiotensine et de diuretiques
WO2003075842A2 (fr) * 2002-03-08 2003-09-18 Teva Pharmeceuticals Usa, Inc. Formulations stables d'inhibiteurs de l'enzyme de conversion de l'angiotensine (ace)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GU L ET AL: "DRUG-EXCIPIENT INCOMPATIBILITY STUDIES OF THE DIPEPTIDE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, MOEXIPRIL HYDROCHLORIDE: DRY POWDER VS WET GRANULATION", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 7, no. 4, 1990, pages 379 - 383, XP009009003, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
NO20090609L (no) 2009-03-13
CA2659814A1 (fr) 2008-01-17
IL196273A0 (en) 2011-08-01
BRPI0621867A2 (pt) 2011-12-20
MX2009000358A (es) 2009-01-27
CN101478983A (zh) 2009-07-08
JP2009542806A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
EP2331074B1 (fr) Granulés, leur procédé de préparation et produits pharmaceutiques les contenant
AU2007297333B2 (en) Solid dosage form of olmesartan medoxomil and amlodipine
US20090324718A1 (en) Imatinib compositions
CA2801020A1 (fr) Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide
EA021317B1 (ru) Монослойные таблетки, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
EP2197428B1 (fr) Composition pharmaceutique amelioree contenant un agent anticonvulsif a base de pyrrolidone et son procede de preparation
EP2508172A1 (fr) Formulations stables et uniformes d'entecavir et procédé de préparation correspondant
US20080008751A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
CA2905423A1 (fr) Comprimes de sovaprevir
WO2014058047A1 (fr) Procédé de production de préparation pharmaceutique contenant un inhibiteur calcique / antagoniste du récepteur d'angiotensine ii
KR101823071B1 (ko) 텔미사르탄-함유 정제의 제조방법
EP3429561A1 (fr) Composition pharmaceutique à doses fixes comprenant de l'amiodipine, du candésartan cilexétil et de l'hydrochlorothiazide pour le traitement de l'hypertension
WO2020109319A1 (fr) Composition pharmaceutique comprenant du ramipril et de l'indapamide
EP1864677B1 (fr) Composition stable comprenant un médicament active sensible à l' humidité et son procédé de fabrication
US20070281000A1 (en) Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
EP2394638A1 (fr) Nouvelles combinaisons pharmaceutiques
EP1889629B1 (fr) Préparation stable contenant une combinaison d'une substance active sensible à l' humidité et d'une deuxième substance active et procédure de fabrication de la préparation.
WO2007142628A1 (fr) Formulation stable contenant un ou des médicaments sensibles à l'humidité et son procédé de fabrication
WO2022153330A1 (fr) Compositions pharmaceutiques comprenant de l'acalabrutinib
WO2008008057A1 (fr) Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci
EP3079672B1 (fr) Composition pharmaceutique comprenant un sel pharmaceutiquement acceptable de rasagiline
KR20090021222A (ko) 수분 민감성 약물 및 제2 약물의 배합을 포함하는 안정한 제제 및 이의 제조 방법
EP3843702A1 (fr) Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil
KR20090016594A (ko) 수분 민감성 약물(들)을 포함하는 안정한 제제 및 이의 제조 절차
WO2024084496A1 (fr) Compositions pharmaceutiques comprenant du maléate d'acalabrutinib

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680055244.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06786901

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10345/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2659814

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 196273

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009519417

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/000358

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009103661

Country of ref document: RU

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 06786901

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020097000857

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0621867

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090109